ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Comment by jjwilsonon Jan 20, 2019 6:18pm

98 Views

Post# 29257624

RE:RE:RE:RE:RE:RE:RE:Clinicals trials?

Yes, "GFY" was over the line and I apologize for that. A moment of weakness. In my defense your post was just the latest in a long series of posts from random "investors" looking for advice on how they can work a quick in and out on PMN to make some fast cash - I'm tired of it and, lately, have developed a tendency to lash out. I'll have to work on that - might be best to just ignore those posts.

Bullboard Posts

Visionstate set to leverage success in the U.S. market